

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI - 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

22nd May, 2019

Department of Corporate Services
Corporate Relation Department
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

BSE Scrip Code: 524516

Subject: Audited Financial Results for the Quarter and Year ended 31st March, 2019 and Auditors' Report thereon

Dear Sir/Madam,

Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2019 duly approved and taken on record by the Board of Directors of the Company.
2. Auditors' Report on the above Financial Results issued by the Statutory Auditors of the Company and taken on record by the Board of Directors of the Company.

Pursuant to SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016; the Company hereby declares that the Statutory Auditors of the Company has issued the Audit Report on the Audited Financial Results of the Company, for the quarter and year ended 31st March, 2019 with unmodified opinion.

The Board Meeting concluded at 6:00 P.M.

You are requested to take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully

For BACIL PHARMA LIMITED


Director



Enclosed: As Above

Bacil Pharma Limited
CIN : {L24200MH1987PLC043427}

Statement of profit and loss for the quarter and year ended March 31, 2019

(Rs. In Lakhs)

Particulars	Quarter ended			Year Ended	
	31st March 2019	31st December 2018	31st March 2018	31st March 2019	31st March 2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Revenue					
Revenue from operations	-	-	-	-	-
Other income	4.71	1.64	1.45	9.41	27.41
Total Revenue	4.71	1.64	1.45	9.41	27.41
Expenses					
Cost of materials consumed	-	-	-	-	-
Purchases of stock-in-trade	-	-	-	-	-
Changes in inventories of work-in-progress and finished goods	-	-	-	-	-
Employee benefit expense	1.22	2.57	4.82	7.87	12.61
Finance costs	-	-	-	-	-
Depreciation and amortisation expense	0.26	0.21	0.57	0.91	1.02
Other expenses	8.56	7.75	6.34	34.97	19.44
Total expenses	10.03	10.53	11.73	43.76	33.07
Profit before exceptional items and tax	(5.32)	(8.90)	(10.28)	(34.35)	(5.66)
Exceptional items	-	-	369.48	-	369.48
Profit / (Loss) from ordinary activities before tax	(5.32)	(8.90)	(379.76)	(34.35)	(375.14)
Tax expense:					
- Current tax	-	-	-	-	-
- Deferred tax	(0.11)	-	2.43	(0.11)	(0.14)
Total tax expense	(0.11)	-	2.43	(0.11)	(0.14)
Profit / (Loss) from ordinary activities after tax	(5.21)	(8.90)	(382.19)	(34.23)	(375.00)
Other comprehensive income (OCI)					
Items that will not be reclassified to profit or loss					
Gain/(loss) recognised on fair valuation of financial assets	8.21	13.58	(49.35)	(0.26)	(56.32)
Income tax related to the above item	(2.00)	(3.36)	11.48	1.92	11.48
	6.21	10.21	(37.87)	1.66	(44.84)
Total Other comprehensive income (net of tax) for the year	6.21	10.21	(37.87)	1.66	(44.84)
Profit/ (loss) for the period	1.00	1.31	(420.06)	(32.58)	(419.84)
Paid up Equity Share Capital (Face Value of Rs. 10/- each)	589.00	589.00	589.00	589.00	589.00
Earnings per equity (EPS) (not annualised) share for profit attributable to owners of Bacil Pharma Limited					
Basic	(0.09)	(0.15)	(6.49)	(0.58)	(6.37)
Diluted	(0.09)	(0.15)	(6.49)	(0.58)	(6.37)

The above Statement of profit & loss should be read in conjunction with the accompanying notes.

Notes:

- The above Financial Results which are published in accordance with the regulation 33 of the Securities and Exchange Board Of India (Listing obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 22th May, 2019.
- The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subject to audit.
- The results for the quarter and the year ended 31st March, 2019 were audited by the Independent Auditors of the Company. An unqualified report was issued by them thereon.
- The Company has single business segment therefore, in the context of Ind'AS 108, disclosure of segment information is not applicable.
- Exceptional item represents diminution in the value of "Fixed assets held for sale", on account of fair value recognition.
- Figures of the previous year/ period/ quarter are regrouped / rearranged / reclassified wherever necessary, to make them comparable.

For and on behalf of the Board
Bacil Pharma Limited



Prakash Shah
(Director)
DIN : 01136800

Place : Mumbai
Date : May 22, 2019

Bacil Pharma Limited
CIN : {L24200MH1987PLC043427}
Balance sheet as at March 31, 2019

(Rs in Lakhs)

	March 31, 2019	March 31, 2018
ASSETS		
Non-current assets		
Property, plant and equipment	2.78	3.31
Financial assets		
Investments	54.82	32.32
Loans	79.95	63.45
Deferred tax assets (net)	11.90	9.88
Total non current assets	149.45	108.96
Current assets		
Financial assets		
Investments	40.99	82.72
Trade receivables	-	1.10
Cash and cash equivalents	6.47	7.90
Bank balance other than cash and cash equivalents above	2.48	19.52
Other current assets	5.96	4.94
Assets Classified as held for sale:		
Property, plant and equipment	250.00	250.00
Total current assets	305.90	366.17
Total assets	455.36	475.13
EQUITY AND LIABILITIES		
Equity		
Equity share capital	652.72	652.72
Other equity	(461.64)	(429.07)
Total equity	191.07	223.65
Liabilities		
Current liabilities		
Financial liabilities		
Borrowings	9.50	-
Trade payables	3.53	0.42
Other financial liabilities	250.24	250.14
Provisions	1.01	0.92
Total current liabilities	264.28	251.48
Total equity and liabilities	455.36	475.13

For and on behalf of the Board



Bacil Pharma Limited

Prakash Shah

(Director)

DIN : 01136800

Place : Mumbai

Date : May 22, 2019



Laxmikant Kabra & Co.

Chartered Accountants

Independent Auditor's Report on Financial Results of Bacil Pharma Limited Pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF
BACIL PHARMA LIMITED

We have audited the accompanying Statement of Financial Results of **Bacil Pharma Limited** ("the company") for the year ended March 31, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular No.CIR/CFD/FAD/62/2016 dated July 5, 2016.

This statement of financial result for the year ended 31st March, 2019, which is the responsibility of the Company's Management and approved by the board of Directors, has been compiled from the related financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement based on our audit of such financial statement.

We have conducted our audit in accordance with the standards on auditing issued by The Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirement and plan and perform the audit to obtain reasonable assurance about whether the Statements are free from material misstatements.

An audit involves performing procedure to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks material misstatements of the Statement, whether due to fraud and error. In making those risk assessments; the auditor considers internal control relevant to the company's preparations and fair preparations of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that our audit provides a reasonable basis for our opinion.



1, Matru Chhaya, M. Karve Road, Opp Dr. Bedekar Hospital, Naupada, Thane (W) 400 602

Email: lk@laxmikantkabra.com, Off.: 25390009 / 25438095, Website: www.laxmikantkabra.com

Independent Auditor's Report on Financial Results of Bacil Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015

In our opinion and to the best of our information and according to the explanations given to us the statement:

- i. Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016; and
- ii. Give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the Net loss and Total comprehensive income and other financial information of the company for the year ended March 31,2019.

Our opinion is not modified in respect of the above matter.

The statements includes the results for the quarter ended March 31, 2019 being the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For, Laxmikant Kabra & Co.

Chartered Accountants

Firm Registration No: 117183W

L. K. Kabra

CA Laxmikant Kabra

(Partner)

Membership No.: 101839



Place: Thane

Date : 22th May, 2019